Clinical Trial

Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.

Name: Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations. — clinical trial record (NCT07392658)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: AMICUTE

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To assess safety and efficacy of amivantamab plus monochemotherapy in terms of ORR, PFS and OS in subjects with EGFR exon20 insertion mutations metastatic non-small cell lung cancer unfit for platinum-based chemotherapy.

Trial Details

NCT Number	NCT07392658
Lead Sponsor	Fondazione Ricerca Traslazionale
Conditions	Metastatic NSCLC - Non-Small Cell Lung Cancer
Enrollment	33 participants
Start Date	2025-12-02
Primary Completion	2027-10 (estimated)
Study Completion	2028-10 (estimated)
Updated on ClinicalTrials.gov	2026-02-06